Purpose To determine if the histology of a breast malignancy influences the appearance of untreated osseous metastases on FDG PET/CT. Methods This retrospective study was performed under IRB waiver. Our Hospital Information System was screened for breast cancer patients who presented with osseous metastases, who underwent FDG PET/CT prior to systemic therapy or radiotherapy from 2009 to 2012. Patients with invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC), or mixed ductal/lobular (MDL) histology were included. Patients with a history of other malignancies were excluded. PET/CT was evaluated, blinded to histology, to classify osseous metastases on a per-patient basis as sclerotic, lytic, mixed lytic/sclerotic, or occult on CT, and to record SUVmax for osseous metastases on PET. Results Following screening, 95 patients who met the inclusion criteria (74 IDC, 13 ILC, and 8 MDL) were included. ILC osseous metastases were more commonly sclerotic and demonstrated lower SUVmax than IDC metastases. In all IDC and MDL patients with osseous metastases, at least one was FDGavid. For ILC, all patients with lytic or mixed osseous metastases demonstrated at least one FDG-avid metastasis; however, in only three of seven patients were sclerotic osseous metastases apparent on FDG PET. Conclusion The histologic subtype of breast cancer affects the appearance of untreated osseous metastases on FDG PET/CT. In particular, non-FDG-avid sclerotic osseous metastases were more common in patients with ILC than in patients with IDC. Breast cancer histology should be considered when interpreting non-FDG-avid sclerotic osseous lesions on PET/ CT, which may be more suspicious for metastases (rather than benign lesions) in patients with ILC.
Introduction
Detection of osseous metastases by imaging is particularly important and can be challenging in patients with breast cancer. Bone is the most common site of distant metastasis in patients with breast cancer, as well as the first site of metastasis in 50 % of patients [1] . Accurate assessment of bone metastases alters clinical management and may decrease patient morbidity [2, 3] .
The most commonly employed strategies for the systemic staging of patients with breast cancer are FDG PET)/CT or CT with 99m Tc-MDP bone scan. The choice between these two strategies is often determined by the perceived value of FDG PET and MDP bone scan for detecting osseous metastases. Multiple authors have concluded that FDG PET is more sensitive for the detection of lytic osseous metastases in patients with breast cancer, while MDP bone scan is more sensitive for the detection of sclerotic osseous metastases [4] [5] [6] . However, many patients in these studies had received prior systemic treatment, and effective systemic treatment results in both decreased FDG avidity and increased sclerosis of osseous lesions [7] [8] [9] . Thus, nonavid sclerotic lesions may represent treated lesions, rather than active malignancy. In a study in which patients with prior systemic treatment were excluded, FDG PET was more sensitive than MDP bone scan when including all patients, but was still associated with a lower visualization rate than MDP bone scan in detecting sclerotic bone metastases [10] .
An important variable that has not been accounted for in these studies is the histology of the breast malignancy. Histology is determined at the time of breast cancer diagnosis, almost always prior to FDG PET/CT. Breast cancers are most commonly invasive ductal carcinomas (IDC), invasive lobular carcinomas (ILC), or mixed ductal and lobular (MDL) in histology, with IDC accounting for about 75 -80 % of primary breast malignancies and ILC accounting for about 10 -15 % [11] [12] [13] . Primary ILC lesions within the breast are more difficult to detect than IDC on imaging studies, including mammography, ultrasonography, and MRI [14, 15] . On FDG PET/CT, primary lobular breast cancers demonstrate lower FDG avidity than comparable primary invasive ductal cancers [16] [17] [18] [19] , suggesting that patients with lobular breast cancers may be more likely to have osseous metastases that are less well visualized with FDG PET than ductal malignancies. Here we investigated whether the histology of a newly diagnosed breast malignancy influences the appearance of osseous metastases on FDG PET/CT.
Materials and methods

Breast cancer patients and histology
This HIPAA-compliant, retrospective study was performed under Institutional Review Board approval. Our Hospital Information System was screened for patients with breast cancer who presented with osseous metastases and underwent PET/CT prior to chemotherapy, hormonal therapy, or radiotherapy from 2009 to 2012. Osseous metastases at presentation was defined as osseous lesions suspicious for metastases on any imaging studies prior to beginning therapy, and verification by histologic sampling or imaging follow-up as described below. Electronic medical records were used to define patients with IDC, ILC, or MDL histology. Patients with the following characteristics were excluded: breast cancer histology other than IDC/ILC/MDL; those who received chemotherapy, hormonal therapy, or radiation therapy for the current breast malignancy; history of prior malignancy (except non-melanoma skin cancer); and synchronous second primary malignancy. Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status was recorded for each patient as positive or negative according to the American Society of Clinical Oncology/College of American Pathologist guidelines [20] . Tumor grades were provided by a board-certified pathologist with specialization in breast malignancies (A.C.).
FDG PET/CT imaging and analysis
All FDG PET/CT scans were performed as integrated studies. FDG PET/CT scans at our institution were performed on hybrid 18 F-FDG PET/CT scanners, with acquisition of images from the mid-skull to upper thigh approximately 60 min after intravenous administration of 12 -15 mCi of 18 F-FDG. Patients fasted for 6 h prior to imaging. Finger-stick blood glucose levels were less than 200 mg/dL at the time of injection. Of the total of 95 FDG PET/CT scans, 5 were performed at an outside institution. While the technique for FDG PET/ CT acquisitions performed by outside institutions could not be controlled for, techniques and images were similar to those of our own studies. FDG PET, CT, and fused FDG PET/CT images were reviewed in multiplanar reconstructions on a GE AW suite. All 18 F-FDG PET/CT studies were reinterpreted by a radiologist (G.U.) with 9 years of 18 F-FDG PET/CT experience, blinded to histology, as well as other imaging and biopsy results.
Morphologic classification of osseous lesions
Osseous metastases were classified into morphologic subtypes based on their appearance on the CT and FDG PET images ( Fig. 1) . High-attenuation osseous lesions on CT images were classified as sclerotic (Fig. 1) , low-attenuation lucent osseous lesions on CT images were classified as lytic, and osseous lesions with substantial sclerotic and lytic components on CT images were classified as mixed lytic/sclerotic. FDG-avid osseous metastases without a correlate on CT images were classified as CT-occult.
As many patients had osseous metastases of more than one morphologic subtype, patients were then categorized according to the morphologic subtypes of osseous metastases on a per-patient basis, as follows:
1. Sclerotic: patients with only sclerotic metastases or sclerotic and occult metastases 2. Lytic: patients with only lytic metastases or lytic and occult metastases 3. Mixed: patients with both lytic and sclerotic metastases, as well as patients with mixed lytic/sclerotic metastases 4. Occult: patients with only occult metastases (evidence of osseous metastases on FDG PET but not CT)
Measurement of FDG avidity
Osseous metastases were deemed FDG-avid when they demonstrated FDG avidity greater than the local background, which was not attributable to a benign cause, such as trauma or degenerative changes. For each patient, the maximum SUV (SUVmax) for the most FDG-avid osseous metastasis was recorded, with the SUVmax representing the single voxel with the greatest SUV adjusted for body weight.
Verification of osseous metastases
Tissue sampling (biopsy) was the preferred method to verify osseous metastases. When histology was not available, follow-up imaging was used. When follow-up imaging was used, lesions had to show typical features of osseous metastases on initial imaging and demonstrate either progression or response to treatment on follow-up.
Statistics
Clinical and imaging characteristics are descriptively summarized using medians and ranges for continuous variables and frequencies and percentages for categorical variables. Summary statistics are provided for the total population and also broken down by histology. For all statistical tests, CT appearance was dichotomized into sclerotic versus all others, and comparisons were made only between IDC and ILC histologic cohorts. The sample size of MDL patients was too small to perform meaningful analyses. The detection rates between IDC and ILC overall and for sclerotic lesions were compared using Fisher's exact test, and the SUVmax values between groups were compared using the Wilcoxon Rank Sum test. Fisher's exact test was also used to assess the relationship between CT morphology and histology and between receptor status and CT appearance. The Kruskal-Wallis test was used to assess the relationship between receptor status and SUVmax. For statistical tests, ER and HER2 were 
Results
A total of 95 patients with breast cancer and osseous metastases at initial presentation met our inclusion and exclusion criteria, including no prior systemic or radiation therapy ( Table 1 ). The histologic subtypes of breast cancer were IDC (74 patients, 78 %), ILC (13 patients, 14 %) and MDL (8 patients, 8 %). Their median age was 53 years, with ages ranging from 29 to 90 years. Of the 95 patients, 58 (61 %) had biopsy confirmation of osseous metastases; in the remaining patients metastases were confirmed by follow-up imaging.
Appearance of osseous metastases categorized by histologic subtype of breast cancer
In the 74 patients with IDC, the most common CT morphology of the osseous metastases was lytic (29/74, 39 %), followed by occult (22/74, 30 %), sclerotic (14/74, 19 %), and mixed (9/74, 12 %; Table 2 ). Notably, all IDC patients with osseous metastases demonstrated at least one osseous metastasis that was FDG-avid, even those with osseous metastases classified as sclerotic (Fig. 2) . Thus, all 74 patients had osseous metastases that were apparent on FDG PET.
In the 8 patients with MDL, the most common CT morphology of the osseous metastases was mixed (4 of 8, 50 %), followed by occult (3 of 8, 38 %), and lytic (1 of 8, 12 %). There were no patients with MDL classified as having sclerotic lesions osseous metastases. All MDL patients with osseous metastases demonstrated at least one osseous metastasis that was FDG-avid. Thus, like IDC patients, all MDL patients had at least one osseous metastasis that was apparent on FDG PET.
In the 13 patients with ILC, the most common CT morphology of the osseous metastases was sclerotic (7 of 13, 54 %), followed by mixed (4 of 13, 31 %), and lytic (2 of 13, 15 %). There were no patients with ILC classified as having only CT occult osseous metastases. All ILC patients with mixed and lytic CT morphology of their osseous metastases demonstrated at least one osseous metastasis that was FDGavid, and thus was apparent on FDG PET (6 of 6, 100 %). However, only 3 of 7 patients with ILC (43 %) classified as having sclerotic osseous metastases demonstrated an FDGavid osseous metastasis. Thus, 4 of the 7 patients with ILC (57 %) classified as having sclerotic osseous metastases had osseous metastases that were not apparent on FDG PET. Of these 4 patients, 3 were diagnosed as having non-FDG-avid osseous metastases by biopsy, and 1 was diagnosed with osseous metastases at follow-up imaging, when growth of the sclerotic osseous metastases was apparent (Fig. 3) . The ability of FDG PET to detect sclerotic osseous metastases in patients with IDC was significantly greater than the ability to detect such metastases in patients with ILC (p=0.006).
The proportions of the CT morphologies in patients with IDC and patients with ILC were significantly different, with a significantly higher proportion of the ILC patients classified as having sclerotic osseous metastases compared with the IDC patients (7 of 13 vs. 14 of 74, p=0.012). 
Discussion
Previous studies have indicated that FDG PET, while highly sensitive for detecting osseous metastases that are lytic on CT, has a lower detection rate for sclerotic osseous metastases [4] [5] [6] 10] . These studies investigated all patients with breast cancer, independent of histologic subtype. Grouping all breast cancer patients together may be because the majority of breast malignancies are of a single histologic subtype: IDC. However, 20 -25 % of breast malignancies are histologic subtypes other than IDC, each with distinct molecular, pathologic, and imaging features. In particular, ILC, the second most common breast cancer histology, which accounts for 10 -15 % of primary breast malignancies [13] , has very distinct imaging features [21] , including the fact that the primary malignancy is less readily appreciable on FDG PET than IDC [16] [17] [18] [19] . The question arises as to whether the histology of the primary breast cancer affects the appearance of osseous metastases on FDG PET/CT. Our study suggests that histologic subtype does affect the appearance of osseous metastases on FDG PET/CT in untreated breast cancer patients. First, FDG avidity of osseous metastases, as measured by SUVmax, was lower in patients with ILC than in those with IDC. Just as primary lobular breast cancers demonstrate lower FDG avidity than comparable invasive ductal cancers [16] [17] [18] [19] , the osseous metastases from these malignancies follow a similar pattern. The lower FDG avidity of ILC tumors may be explained by lower cellular density, proliferation rate, and number of GLUT transporters in this breast cancer histology than in the more common IDC [16, 18] . Second, osseous metastases were more commonly sclerotic on CT in patients with ILC than in patients with IDC. Why there tends to be more attenuating bone in ILC than in IDC osseous metastases is unclear. A possible explanation could be greater bone remodeling in ILC osseous metastases, owing to slower tumor growth or less dense packing of tumor cells, although this is only a hypothesis.
Distinguishing non-FDG-avid sclerotic osseous metastases from non-FDG-avid benign osseous lesions such as bone islands is of clinical importance. For example, the patient in Fig. 2 demonstrated small sclerotic lesions that could have been misinterpreted as benign were it not for the FDG avidity seen on FDG PET. In this study, all 14 IDC and MDL patients with sclerotic osseous metastases had appreciable metastases on FDG PET, while 4 of 7 ILC patients with sclerotic osseous metastases did not have appreciable metastases on FDG PET. This difference was statistically significant (p=0.006). This is an important distinction, as knowledge of the histologic subtype of breast cancer can assist in the interpretation of non-FDG-avid sclerotic osseous lesions. When small non-FDGavid sclerotic osseous lesions are seen on PET/CT images in patients with untreated breast cancer, the histology of the breast malignancy should be considered. In ILC patients, the propensity for sclerotic osseous metastases to be non-FDGavid should be raised, and consideration given to performing a biopsy or obtaining follow-up imaging before excluding metastatic disease. In untreated IDC patients, our study suggests that sclerotic osseous lesions, when none is FDG avid, are probably benign. This distinction is relevant only in patients with breast cancer who have not received systemic treatment, since following systemic treatment, non-FDG-avid sclerotic lesions may represent treated metastases in patients with both ILC and IDC.
In this study we evaluated on a per-patient, rather than a per-lesion, basis. The clinically significant determination in patients with newly diagnosed breast cancer is whether there are or are not osseous metastases, which will affect treatment algorithms far more than the number of osseous metastases. Indeed, in a single patient there may be populations of both FDG-avid and non-FDG-avid osseous metastases.
Our results indicate that the value of FDG PET may be greater in patients with IDC than in those with ILC, particularly when evaluating for osseous metastases. In 30 % (22) of the 74 untreated IDC patients with osseous metastases, the metastases were occult on CT, and only detectable by PET. There were no untreated ILC patients with osseous metastases who were identified only on PET. Indeed, in 31 % (4) of 13 ILC patients with osseous metastases, the metastases were occult on PET and identified only on the CT component of PET/CT. FDG PET may still detect lesions outside the bone [22] [23] [24] , and FDG avidity may be used to predict survival in patients with metastatic breast cancer [25, 26] .
It is difficult to establish a large cohort of breast cancer patients with FDG PET/CT performed prior to treatment that could alter the appearance of osseous metastases on FDG PET/CT. While small, the size of our cohort was relatively large in view of our specific inclusion requirements. In addition, the large proportion of patients with biopsy proof of osseous malignancy is a strength of this analysis. Although tumor grade could be proposed as a factor that could influence FDG avidity, our analysis did not find a difference in SUVmax of osseous metastases between grade 1/2 tumors and grade 3 tumors (p=0.96). This is similar to a prior study that failed to show a significant correlation between breast cancer tumor grade and FDG avidity of the primary breast malignancy [19] .
The limitations of this study include its retrospective design, which introduces inherent biases. Additionally, some subgroups were small, especially the MDL subgroup (8 patients), and we could not perform meaningful analyses on this subgroup. Furthermore, only 7 patients with ILC and 14 with IDC had sclerotic metastases.
Conclusion
Our results demonstrate that the histologic subtype of breast cancer is significantly associated with the appearance of untreated osseous metastases on FDG PET/CT. Untreated osseous metastases were more often sclerotic in patients with ILC than in those with IDC. Osseous metastases in patients with ILC demonstrated lower FDG avidity than those in IDC patients, and non-FDG-avid sclerotic osseous metastases were significantly more common in untreated patients with ILC than with IDC. Since the histology of breast cancer is usually known at the time of diagnosis, this information should be considered when interpreting osseous lesions on PET/CT. The value of FDG PET may be greater in patients with IDC than in those with ILC, particularly when evaluating for osseous metastases.
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